Baxter Pharmaceutical Solutions will resume production of its Baxter Pharmaceutical products in the UK.
The company has been in talks with the UK Government to resume production.
The UK Government has recently issued a request for proposals (RFP) to develop and launch a manufacturing facility to meet the growing demand for Baxter Pharmaceutical solutions, Baxter said in a statement.
“This new facility will allow us to continue our growth into new areas of business and we look forward to returning to the UK market with the new facility, which will allow our UK manufacturing team to accelerate and ramp up our current manufacturing and supply chain,” said Baxter CEO, Andy Wood, in a press release.
The facility will be in the heart of the City of London.
The new facility would be built at the end of a five-year development phase and would be fully operational by mid-2018, according to Baxter.
Baxter said the RFP will allow the company to start to accelerate its operations and to build on its strengths in the area of pharmaceutical manufacturing.
“The UK is a strong market and a strong partner for us to further expand our international reach, and this is a key part of the strategy we are using to grow in the world,” Wood said.
Baxter’s RFP is expected to close by the end to early 2019.
Baxter is a joint venture between Baxter Pharmaceutical, Baxter, and Valeant Pharmaceuticals, which owns its drug division.